Shreyaskumar R. Patel, MD: Different Types of Liposarcoma

Shreyaskumar R. Patel, MD: Principle Treatment Goals for This Patient

Shreyaskumar R. Patel, MD: Pattern of This Patient's Metastatic Disease

Shreyaskumar R. Patel, MD: Trabectedin in Advanced, Invasive Myxoid Liposarcoma

Shreyaskumar R. Patel, MD: Clinical Data Supporting the Use of Trabectedin

Shreyaskumar R. Patel, MD: Main Indication for Dose Reduction

Jonathan C. Trent, MD, PhD: Different Types of Liposarcoma

Jonathan C. Trent, MD, PhD: Principle Treatment Goals for This Patient

Jonathan C. Trent, MD, PhD: Pattern of This Patient's Metastatic Disease

Jonathan C. Trent, MD, PhD: Trabectedin in Advanced, Invasive Myxoid Liposarcoma

Jonathan C. Trent, MD, PhD: Clinical Data Supporting the Use of Trabectedin

Jonathan C. Trent, MD, PhD: Main Indication for Dose Reduction

Michael C is a 59-year-old social worker from Los Angeles California; his medical history is notable for obesity, COPD, and mild hypertension.

In January of 2014, he presents to his PCP with complaints of right lower leg pain of several weeks&rsquo; duration

Physical exam was unremarkable except for swelling of the lower right calf; x-ray of the affected leg was negative for fracture

MRI scan of the lower right calf showed a 20 cm well defined lobular mass arising between the gastrocnemius and soleus

Biopsy of the mass showed myxoid liposarcoma with round cell component. Patient underwent en bloc resection of the tumor following preoperative radiotherapy

Gross examination showed the tumor to be 10 &times; 8 &times; 15 cm with gelatinous brownish appearance

In September of 2014, Michael returns for follow up and his CT scan shows a 4 cm posterior mediastinal mass, and a 6 cm perinephric mass suspicious for metastatic disease. He initiates treatment with anthracycline and ifosfamide chemotherapy (6 cycles) for recurrent disease and shows a partial response.

In May of 2015, he returns for follow up with intermittent chest and lower back pain; CT scan is consistent with progression of the mediastinal and perinephric masses, and bone scan shows new lesions occurring in the L2 and L3 lumbar vertebrae

At recurrence, liver and renal function and CBC are within normal limits, and his ECOG performance status is 1

He received treatment with trabectedin (1.5 mg/m2 24-hr infusion given every 3 week)

At the 2nd cycle he develops febrile neutropenia (ANC< 500 cells/mm3) requiring hospitalization

The oncologist reduces his trabectedin dose to 1.2 mg/m2; he continues therapy

Within 1 week, he shows clinical improvement and CT scan shows slight improvement

Case Based Peer Perspectives

Sarcoma

Soft Tissue Sarcoma with Jonathan C. Trent, MD, PhD and Shreyaskumar R. Patel, MD